2026 PanKind Pancreatic Cancer Research Foundation Grants

Purpose and Program Overview

The 2026 PanKind Competitive Grant Round supports research that could significantly improve pancreatic cancer outcomes, inspiring confidence in the potential impact of your work.

The program offers up to $300,000 per grant across three funding categories, supporting research at different stages of development, from early-stage innovation through to advanced, clinically focused projects. Funding is directed toward Australian researchers and institutions undertaking work with a logical and demonstrable application to improving pancreatic cancer outcomes.

Beyond funding, this grant round offers a chance to contribute to PanKind’s mission to triple survival rates by 2030, motivating your participation in advancing impactful research.

Key Grant Details

• Grant amount: Up to $300,000 per grant, depending on category
• Applications open: Tuesday, 12 May 2026
• Applications close: Friday, 14 August 2026, 5:00 PM AEST
• Grants announced: Early November 2026
• Eligible applicants: Researchers across diverse scientific disciplines whose work has a clear application to pancreatic cancer outcomes; commercial entities, including biotechnology and pharmaceutical organisations, may also apply
• Co-contribution: Not specified as a mandatory requirement in the published guidelines
• Location/applicability: The Principal Investigator must be based in Australia, and the administering institution must be an Australian organisation

Priority Sectors

The 2026 grant round is focused specifically on pancreatic cancer research, with priority given to two key areas:

• Early Detection – strategies and tools to identify pancreatic cancer earlier
• New Treatments – therapies, diagnostics, and quality-of-care improvements

Within these areas, the program is open to a broad range of scientific disciplines, provided the proposed research has a clear and demonstrable pathway to improving pancreatic cancer outcomes.

Funding Scope

The 2026 round comprises three funding categories:

• Early Detection Accelerator Grant (new for 2026)
  • Funding: $300,000
  • Duration: 2 years
  • Focus: Clinically ready early-detection strategies progressing toward clinical application
  • New Treatment Innovation Grant Funding: $100,000
  • Duration: 1 year
  • Focus: Early-stage research into new treatments, diagnostics, or quality-of-care improvements
  • New Treatment Accelerator Grant Funding: $300,000
  • Duration: 2 years
  • Focus: Advanced research fast-tracking promising treatments from the laboratory to clinical application

Eligibility Criteria

• The Principal Investigator must be based in Australia, with the administering institution an Australian organisation
• Only one application per institution may be submitted for each grant category
• An individual may be named as Principal Investigator on no more than one application across all categories in the same round
• Applicants and research team members may be funded at a maximum of 1.0 full-time equivalent across the project
• Applicants who currently hold a Pankind grant as Principal Investigator must have that grant conclude within the current calendar year
• Biotechnology, pharmaceutical, and other commercial entities are eligible to apply, though Pankind reserves the right to vary funding terms for successful commercial applicants
• Projects involving human biospecimens or data require a letter of support from an appropriate repository or collection at the time of application, along with clearly outlined ethics and governance arrangements
• The administering institution must agree to the terms of Pankind’s Research Funding Agreement
• Applicants must disclose any potential overlap with other current or pending research funding

Eligible Activities and Expenses

• Early-stage and proof-of-concept research into new treatments, diagnostics, or quality-of-care improvements
• Advanced, developed research projects progressing toward clinical studies or clinical application
• Biomarker development, imaging tools, and risk stratification approaches for early Detection
• Scaling up of existing or prior research, including work that builds on previous Pankind-funded studies
• Activities aligned with Pankind’s Permitted Use of Funds guidelines, as outlined in the funding agreement

Assessment Process

The 2026 grant round is competitive. All applications are assessed by PanKind’s Scientific Advisory Panel, together with selected external medical experts, against the following criteria:

• Investigator team capability – relevant expertise, track record, and capacity to deliver the project
• Novelty and innovation – originality of the research concept, methodology, and approach
• Impact on pancreatic cancer survival – contribution toward PanKind’s mission to triple survival by 2030, including a feasible pathway to clinical application
• Scientific quality and feasibility – rigour of study design, ethical considerations, and realism of the proposed timeline
• Budget – not separately scored, but reviewed to confirm that funding requested is appropriate, justified, and proportionate to the proposed scope of work

Recent Program Updates

• The Early Detection Accelerator Grant is a new category introduced for 2026, building on proof-of-concept and feasibility work funded since 2021
• The two-tier New Treatment structure (Innovation and Accelerator grants), first introduced in 2025, continues in 2026 to support research at both early and advanced stages
• All applications must now be submitted through PanKind’s online grant portal; no soft copies will be accepted
• The Pankind Research Funding Agreement is undergoing revision, with an updated version expected to be available in late May 2026

Application Tips

• Confirm eligibility against all stated criteria before commencing an application, particularly institutional and Principal Investigator location requirements
• Set up a grant portal account well in advance of the closing date to allow time to resolve any technical issues
• Clearly demonstrate the stage of research development and ensure the chosen category (Innovation versus Accelerator, or Early Detection versus New Treatment) matches the project’s maturity
• Prepare supporting documentation early, including ethics approvals, letters of support, and details of any prior related funding
• Where applicable, clearly outline the role of each co-investigator and disclose any overlapping funding applications
• Align the proposal with PanKind’s stated mission and assessment criteria, particularly the pathway to clinical application and impact on survival outcomes

Where to Get Help

Consider consulting a grant specialist like Pattens Group for a personalised eligibility assessment and expert assistance in preparing a strong, compliant and competitive application. Contact us today and get connected with Australia’s best grant specialist, boasting over 35 years of experience in the industry and a 100% success rate. For official guidelines, application details, templates, and further information, visit the official website of the PanKind Pancreatic Cancer Research Foundation and other associated Australian government websites.